Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Hair Growth Supplement And Treatment Market

ID: MRFR/HC/29426-HCR
100 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Hair Growth Supplement and Treatment Market Research Report By Supplement Type (Biotin Supplements, Collagen Supplements, Keratin Supplements, Vitamin D Supplements, Iron Supplements), By Treatment Type (Laser Therapy, Platelet-Rich Plasma (PRP) Therapy, Microneedling, Hair Transplants, Scalp Massaging), By Application (Male Pattern Baldness, Female Pattern Baldness, Alopecia Areata, Telogen Effluvium, Other Hair Loss Conditions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Hair Growth Supplement And Treatment Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Supplement Type (USD Billion)
  49.     4.1.1 Biotin Supplements
  50.     4.1.2 Collagen Supplements
  51.     4.1.3 Keratin Supplements
  52.     4.1.4 Vitamin D Supplements
  53.     4.1.5 Iron Supplements
  54.   4.2 Healthcare, BY Treatment Type (USD Billion)
  55.     4.2.1 Laser Therapy
  56.     4.2.2 Platelet-Rich Plasma (PRP) Therapy
  57.     4.2.3 Microneedling
  58.     4.2.4 Hair Transplants
  59.     4.2.5 Scalp Massaging
  60.   4.3 Healthcare, BY Application (USD Billion)
  61.     4.3.1 Male Pattern Baldness
  62.     4.3.2 Female Pattern Baldness
  63.     4.3.3 Alopecia Areata
  64.     4.3.4 Telogen Effluvium
  65.     4.3.5 Other Hair Loss Conditions
  66.   4.4 Healthcare, BY Region (USD Billion)
  67.     4.4.1 North America
  68.       4.4.1.1 US
  69.       4.4.1.2 Canada
  70.     4.4.2 Europe
  71.       4.4.2.1 Germany
  72.       4.4.2.2 UK
  73.       4.4.2.3 France
  74.       4.4.2.4 Russia
  75.       4.4.2.5 Italy
  76.       4.4.2.6 Spain
  77.       4.4.2.7 Rest of Europe
  78.     4.4.3 APAC
  79.       4.4.3.1 China
  80.       4.4.3.2 India
  81.       4.4.3.3 Japan
  82.       4.4.3.4 South Korea
  83.       4.4.3.5 Malaysia
  84.       4.4.3.6 Thailand
  85.       4.4.3.7 Indonesia
  86.       4.4.3.8 Rest of APAC
  87.     4.4.4 South America
  88.       4.4.4.1 Brazil
  89.       4.4.4.2 Mexico
  90.       4.4.4.3 Argentina
  91.       4.4.4.4 Rest of South America
  92.     4.4.5 MEA
  93.       4.4.5.1 GCC Countries
  94.       4.4.5.2 South Africa
  95.       4.4.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 Nutrafol (US)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Viviscal (IE)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 Rogaine (US)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Hairfinity (US)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Nioxin (US)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 Pura D'or (US)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Kérastase (FR)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Aveda (US)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 Hims (US)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.     5.2.10 Keeps (US)
  167.       5.2.10.1 Financial Overview
  168.       5.2.10.2 Products Offered
  169.       5.2.10.3 Key Developments
  170.       5.2.10.4 SWOT Analysis
  171.       5.2.10.5 Key Strategies
  172.   5.3 Appendix
  173.     5.3.1 References
  174.     5.3.2 Related Reports
  175. 6 LIST OF FIGURES
  176.   6.1 MARKET SYNOPSIS
  177.   6.2 NORTH AMERICA MARKET ANALYSIS
  178.   6.3 US MARKET ANALYSIS BY SUPPLEMENT TYPE
  179.   6.4 US MARKET ANALYSIS BY TREATMENT TYPE
  180.   6.5 US MARKET ANALYSIS BY APPLICATION
  181.   6.6 CANADA MARKET ANALYSIS BY SUPPLEMENT TYPE
  182.   6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE
  183.   6.8 CANADA MARKET ANALYSIS BY APPLICATION
  184.   6.9 EUROPE MARKET ANALYSIS
  185.   6.10 GERMANY MARKET ANALYSIS BY SUPPLEMENT TYPE
  186.   6.11 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
  187.   6.12 GERMANY MARKET ANALYSIS BY APPLICATION
  188.   6.13 UK MARKET ANALYSIS BY SUPPLEMENT TYPE
  189.   6.14 UK MARKET ANALYSIS BY TREATMENT TYPE
  190.   6.15 UK MARKET ANALYSIS BY APPLICATION
  191.   6.16 FRANCE MARKET ANALYSIS BY SUPPLEMENT TYPE
  192.   6.17 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
  193.   6.18 FRANCE MARKET ANALYSIS BY APPLICATION
  194.   6.19 RUSSIA MARKET ANALYSIS BY SUPPLEMENT TYPE
  195.   6.20 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
  196.   6.21 RUSSIA MARKET ANALYSIS BY APPLICATION
  197.   6.22 ITALY MARKET ANALYSIS BY SUPPLEMENT TYPE
  198.   6.23 ITALY MARKET ANALYSIS BY TREATMENT TYPE
  199.   6.24 ITALY MARKET ANALYSIS BY APPLICATION
  200.   6.25 SPAIN MARKET ANALYSIS BY SUPPLEMENT TYPE
  201.   6.26 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
  202.   6.27 SPAIN MARKET ANALYSIS BY APPLICATION
  203.   6.28 REST OF EUROPE MARKET ANALYSIS BY SUPPLEMENT TYPE
  204.   6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
  205.   6.30 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  206.   6.31 APAC MARKET ANALYSIS
  207.   6.32 CHINA MARKET ANALYSIS BY SUPPLEMENT TYPE
  208.   6.33 CHINA MARKET ANALYSIS BY TREATMENT TYPE
  209.   6.34 CHINA MARKET ANALYSIS BY APPLICATION
  210.   6.35 INDIA MARKET ANALYSIS BY SUPPLEMENT TYPE
  211.   6.36 INDIA MARKET ANALYSIS BY TREATMENT TYPE
  212.   6.37 INDIA MARKET ANALYSIS BY APPLICATION
  213.   6.38 JAPAN MARKET ANALYSIS BY SUPPLEMENT TYPE
  214.   6.39 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
  215.   6.40 JAPAN MARKET ANALYSIS BY APPLICATION
  216.   6.41 SOUTH KOREA MARKET ANALYSIS BY SUPPLEMENT TYPE
  217.   6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
  218.   6.43 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  219.   6.44 MALAYSIA MARKET ANALYSIS BY SUPPLEMENT TYPE
  220.   6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
  221.   6.46 MALAYSIA MARKET ANALYSIS BY APPLICATION
  222.   6.47 THAILAND MARKET ANALYSIS BY SUPPLEMENT TYPE
  223.   6.48 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
  224.   6.49 THAILAND MARKET ANALYSIS BY APPLICATION
  225.   6.50 INDONESIA MARKET ANALYSIS BY SUPPLEMENT TYPE
  226.   6.51 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
  227.   6.52 INDONESIA MARKET ANALYSIS BY APPLICATION
  228.   6.53 REST OF APAC MARKET ANALYSIS BY SUPPLEMENT TYPE
  229.   6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
  230.   6.55 REST OF APAC MARKET ANALYSIS BY APPLICATION
  231.   6.56 SOUTH AMERICA MARKET ANALYSIS
  232.   6.57 BRAZIL MARKET ANALYSIS BY SUPPLEMENT TYPE
  233.   6.58 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
  234.   6.59 BRAZIL MARKET ANALYSIS BY APPLICATION
  235.   6.60 MEXICO MARKET ANALYSIS BY SUPPLEMENT TYPE
  236.   6.61 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
  237.   6.62 MEXICO MARKET ANALYSIS BY APPLICATION
  238.   6.63 ARGENTINA MARKET ANALYSIS BY SUPPLEMENT TYPE
  239.   6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
  240.   6.65 ARGENTINA MARKET ANALYSIS BY APPLICATION
  241.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY SUPPLEMENT TYPE
  242.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  243.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  244.   6.69 MEA MARKET ANALYSIS
  245.   6.70 GCC COUNTRIES MARKET ANALYSIS BY SUPPLEMENT TYPE
  246.   6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
  247.   6.72 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  248.   6.73 SOUTH AFRICA MARKET ANALYSIS BY SUPPLEMENT TYPE
  249.   6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
  250.   6.75 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  251.   6.76 REST OF MEA MARKET ANALYSIS BY SUPPLEMENT TYPE
  252.   6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
  253.   6.78 REST OF MEA MARKET ANALYSIS BY APPLICATION
  254.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  255.   6.80 RESEARCH PROCESS OF MRFR
  256.   6.81 DRO ANALYSIS OF HEALTHCARE
  257.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  258.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  259.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  260.   6.85 HEALTHCARE, BY SUPPLEMENT TYPE, 2024 (% SHARE)
  261.   6.86 HEALTHCARE, BY SUPPLEMENT TYPE, 2024 TO 2035 (USD Billion)
  262.   6.87 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  263.   6.88 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
  264.   6.89 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  265.   6.90 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  266.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  267. 7 LIST OF TABLES
  268.   7.1 LIST OF ASSUMPTIONS
  269.     7.1.1
  270.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  271.     7.2.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  272.     7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  273.     7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
  274.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  275.     7.3.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  276.     7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  277.     7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
  278.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  279.     7.4.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  280.     7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  281.     7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
  282.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  283.     7.5.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  284.     7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  285.     7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
  286.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  287.     7.6.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  288.     7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  289.     7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
  290.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  291.     7.7.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  292.     7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  293.     7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
  294.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  295.     7.8.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  296.     7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  297.     7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
  298.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  299.     7.9.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  300.     7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  301.     7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
  302.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  303.     7.10.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  304.     7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  305.     7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
  306.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  307.     7.11.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  308.     7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  309.     7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
  310.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  311.     7.12.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  312.     7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  313.     7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
  314.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  315.     7.13.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  316.     7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  317.     7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
  318.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  319.     7.14.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  320.     7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  321.     7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
  322.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  323.     7.15.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  324.     7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  325.     7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
  326.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  327.     7.16.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  328.     7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  329.     7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
  330.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  331.     7.17.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  332.     7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  333.     7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
  334.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  335.     7.18.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  336.     7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  337.     7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
  338.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  339.     7.19.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  340.     7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  341.     7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
  342.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  343.     7.20.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  344.     7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  345.     7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
  346.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  347.     7.21.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  348.     7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  349.     7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
  350.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  351.     7.22.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  352.     7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  353.     7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
  354.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  355.     7.23.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  356.     7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  357.     7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
  358.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  359.     7.24.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  360.     7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  361.     7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
  362.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  363.     7.25.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  364.     7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  365.     7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
  366.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  367.     7.26.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  368.     7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  369.     7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
  370.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  371.     7.27.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  372.     7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  373.     7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
  374.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  375.     7.28.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  376.     7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  377.     7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
  378.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  379.     7.29.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  380.     7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  381.     7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
  382.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  383.     7.30.1 BY SUPPLEMENT TYPE, 2025-2035 (USD Billion)
  384.     7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  385.     7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
  386.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  387.     7.31.1
  388.   7.32 ACQUISITION/PARTNERSHIP
  389.     7.32.1

Healthcare Market Segmentation

Healthcare By Supplement Type (USD Billion, 2025-2035)

  • Biotin Supplements
  • Collagen Supplements
  • Keratin Supplements
  • Vitamin D Supplements
  • Iron Supplements

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Laser Therapy
  • Platelet-Rich Plasma (PRP) Therapy
  • Microneedling
  • Hair Transplants
  • Scalp Massaging

Healthcare By Application (USD Billion, 2025-2035)

  • Male Pattern Baldness
  • Female Pattern Baldness
  • Alopecia Areata
  • Telogen Effluvium
  • Other Hair Loss Conditions

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions